BETOPTIC S Drug Patent Profile
✉ Email this page to a colleague
When do Betoptic S patents expire, and what generic alternatives are available?
Betoptic S is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in BETOPTIC S is betaxolol hydrochloride. There are eleven drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the betaxolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Betoptic S
A generic version of BETOPTIC S was approved as betaxolol hydrochloride by EPIC PHARMA on October 22nd, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BETOPTIC S?
- What are the global sales for BETOPTIC S?
- What is Average Wholesale Price for BETOPTIC S?
Summary for BETOPTIC S
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 137 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,685 |
| Drug Prices: | Drug price information for BETOPTIC S |
| What excipients (inactive ingredients) are in BETOPTIC S? | BETOPTIC S excipients list |
| DailyMed Link: | BETOPTIC S at DailyMed |
Recent Clinical Trials for BETOPTIC S
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Alcon Research | Phase 3 |
Pharmacology for BETOPTIC S
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
US Patents and Regulatory Information for BETOPTIC S
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | BETOPTIC S | betaxolol hydrochloride | SUSPENSION/DROPS;OPHTHALMIC | 019845-001 | Dec 29, 1989 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for BETOPTIC S
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Novartis | BETOPTIC S | betaxolol hydrochloride | SUSPENSION/DROPS;OPHTHALMIC | 019845-001 | Dec 29, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Novartis | BETOPTIC S | betaxolol hydrochloride | SUSPENSION/DROPS;OPHTHALMIC | 019845-001 | Dec 29, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for BETOPTIC S
See the table below for patents covering BETOPTIC S around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Germany | 68913979 | ⤷ Sign Up | |
| Australia | 4575389 | ⤷ Sign Up | |
| Japan | H0725698 | ⤷ Sign Up | |
| Mexico | 9603060 | COMPOSICIONES PARA EL TRATAMIENTO DE GLAUCOMA QUE COMPRENDEN PILOCARPINA Y UN BETA-BLOQUEADOR. (COMPOSITIONS FOR TREATMENT OF GLAUCOMA COMPRISING PILOCARPINE AND A BETA-BLOCKER.) | ⤷ Sign Up |
| Australia | 621692 | ⤷ Sign Up | |
| South Africa | 8909204 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
